Expression of membrane glycoproteins in L6 myoblasts during the course of myogenesis was investigated. The effects of several inhibitors of myoblast fusion and differentiation were also studied. The predominant change in plasma membrane proteins concomitant with fusion was the reduction in the expression of a major 105-kDa glycoprotein and the appearance of a 90-kDa glycoprotein. This change was blocked by bromodeoxyuridine and two metalloendoprotease inhibitors, phenanthroline and benzyloxycarbonyl-Ser-Leu-NH2, all of which have been shown to inhibit myoblast fusion. The nature of this inhibition suggests a role for an endogenous metalloendoprotease in myoblast commitment to terminal differentiation. The possible function of the developmentally regulated glycoproteins in myogenesis is also discussed. (1). This process involves the fusion of myoblasts and the synthesis of muscle-specific proteins, such as myosin, creatine kinase, and acetylcholine receptors (1-3). Little is known about the molecular nature of the commitment process or the mechanisms of fusion and differentiation.There is convincing evidence to indicate that membrane glycoproteins mediate the adhesion and fusion of myoblasts (4,5). However, no protein that plays a direct role in either of these processes has been identified. One strategy for the identification of these proteins is to raise monoclonal antibodies against the myoblast surface and then to screen them for their inhibition ofcell-cell adhesion or fusion (or both). So far this approach has yielded antibodies that inhibit only cell-substratum adhesion (6).Another approach that several laboratories have undertaken is to examine the changes in myoblast membrane proteins during myogenesis. The effect of BrdUrd, a potent inhibitor of myoblast fusion and differentiation (7), has also been studied. Only minor changes in membrane proteins have been reported and no good correlation with the adhesion or fusion process has been found (5,8,9).Recent studies by Couch and Strittmatter (10, 11) indicate that an endogenous metalloendoprotease plays a role in myoblast fusion. Inhibition of the metalloendoprotease by various inhibitors was shown to correlate with the inhibition of myoblast fusion in primary rat myoblast cultures as well as in the rat cell line L6. These inhibitors included 1,10-phenanthroline (a divalent cation chelator with a high affinity for zinc) and benzyloxycarbonyl-Ser-Leu-NH2 (Cbz-SerLeu-NH2) (a synthetic peptide that competes with substrates of various metalloendoproteases). These inhibitors were also shown to inhibit the endogenous metalloendoprotease activity in the cell extracts of L6 myoblasts (11). The cellular target(s) of this endogenous metalloendoprotease has not been identified. In addition, although these authors have clearly documented the involvement of a metalloendoprotease in myoblast fusion, they have not investigated the possibility that the metalloendoprotease might actually be involved in the initiation of myoblast commitment to terminal differentiati...